Allegro Ophthalmics, LLC

Allegro Ophthalmics is focused on developing innovative therapies for ocular diseases, especially integrin-regulating treatments that address critical health issues in eye care. Allegro Ophthalmics specializes in creating therapies for ocular diseases and was founded in 2011 in San Juan Capistrano, US. The company was acquired by Bausch Health Companies Inc. in September 2020 for USD 50 mn.

The CEO is Vicken Karageozian and the founder is John Park, who has a history of involvement in other biotech ventures. Allegro has completed 7 deals, with the most recent occurring on September 21, 2020. Allegro Ophthalmics specializes in the development of innovative therapies for ocular diseases, with a focus on integrin-regulating treatments. Their flagship product, Risuteganib, addresses unmet needs in managing intermediate dry age-related macular degeneration (AMD) and dry eye disease, targeting patients with limited responses to current treatments.

The company markets its products primarily in North America and selected regions in Asia, focusing on areas with a high prevalence of dry AMD and dry eye disease. Allegro Ophthalmics generates revenue through partnerships and collaborations with pharmaceutical companies and healthcare providers, particularly for clinical trials and product development. They collaborate with organizations like AffaMed Therapeutics for international clinical trials, especially in China. Revenue structures include milestone payments upon reaching specific clinical trial phases and potential future royalties on sales of Risuteganib, with pricing determined through negotiations with healthcare providers and distributors.

Following the acquisition by Bausch Health Companies Inc. , Allegro Ophthalmics plans to utilize the USD 50 mn from the acquisition to enhance its clinical pipeline and advance the development of new products. The company is focusing on expanding its market presence, particularly in Asia, aiming to launch new therapies by 2022. Allegro will leverage recent funding to support these initiatives and strengthen its position in the ocular therapeutics market.